Diabetes

Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution

Retrieved on: 
Thursday, May 9, 2024

Powered by Rimidi, the Eversense CGM + RPM solution is intended to seamlessly and securely push patient glucose data to the most widely used EHR systems, to provide direct access for healthcare providers.

Key Points: 
  • Powered by Rimidi, the Eversense CGM + RPM solution is intended to seamlessly and securely push patient glucose data to the most widely used EHR systems, to provide direct access for healthcare providers.
  • “The Eversense RPM Program™ is the next step in our roadmap to combine long-term implantable CGM technology with advanced analytics and personalized health services into a comprehensive diabetes solution.
  • Eversense RPM will arm providers with powerful data to optimize care in between office visits where 99% of diabetes management takes place,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.
  • A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, May 9, 2024

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points: 
  • Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
  • Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, May 9, 2024

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points: 
  • Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
  • Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Med-Bev Welcomes Mark Andrews as Its Partner and Spokesperson for Its Natural Diabetic-Friendly Drink Mix

Retrieved on: 
Thursday, May 9, 2024

HACKENSACK, N.J., May 9, 2024 /PRNewswire/ -- Med-Bev, a pioneering health and wellness company, is thrilled to announce Baltimore tight end, Mark Andrews, as a collaborative partner and spokesperson for their Natural Diabetic-Friendly Drink Mix.

Key Points: 
  • HACKENSACK, N.J., May 9, 2024 /PRNewswire/ -- Med-Bev, a pioneering health and wellness company, is thrilled to announce Baltimore tight end, Mark Andrews, as a collaborative partner and spokesperson for their Natural Diabetic-Friendly Drink Mix.
  • Med-Bev's Natural Diabetic-Friendly Drink Mix offers a convenient solution for individuals seeking to manage their blood sugar without sacrificing flavor or convenience.
  • "Our Natural Diabetic-Friendly Drink Mix is a game-changer for anyone looking for a great tasting healthy beverage that won't raise their blood sugar.
  • Med-Bev's Natural Diabetic-Friendly Drink Mix has an array of mouthwatering flavors like Berry Lemonade, Limeade, and Peach Iced Tea, guaranteeing an option for every palate.

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Retrieved on: 
Thursday, May 9, 2024

LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
  • As of March 31, 2024, MeiraGTx had cash and cash equivalents of approximately $119.2 million and in April 2024, the Company collected $19.7 million in receivables which were due in the first quarter of 2024, effectively increasing the cash balance to $138.9 million.
  • The increase of $0.6 million was due to higher interest rates and cash balances during 2024.
  • Interest expense was $3.3 million for the three months ended March 31, 2024, compared to $3.1 million for the three months ended March 31, 2023.

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, May 9, 2024

GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024
    Webcast to be held today, May 9, 2024, at 8:30 am ET
    GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • With these promising data, we are preparing for our End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), which is expected to occur late in the third quarter.
  • Financial Results for the Three Months Ended March 31, 2024
    Altimmune had cash, cash equivalents and short-term investments totaling $182.1 million at March 31, 2024.
  • Research and development expenses were $21.5 million for the three months ended March 31, 2024, compared to $17.2 million in the same period in 2023.

Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea

Retrieved on: 
Thursday, May 9, 2024

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced the early completion of enrollment in its LunAIRo Phase 3 study designed to examine the efficacy and safety of its lead candidate AD109 (aroxybutynin/atomoxetine) compared to placebo at six months and one year. The company believes AD109 has the potential to be the first nighttime oral pharmacologic treatment for people with OSA who are either intolerant of or refuse to use positive airway pressure (PAP) therapy. Apnimed’s second, large pivotal Phase 3 randomized controlled trial, SynAIRgy, is continuing its enrollment. Topline Phase 3 data for both LunAIRo and SynAIRgy are expected in Mid-2025.

Key Points: 
  • Apnimed’s second, large pivotal Phase 3 randomized controlled trial, SynAIRgy, is continuing its enrollment.
  • Topline Phase 3 data for both LunAIRo and SynAIRgy are expected in Mid-2025.
  • The LunAIRo Study is a randomized, double blind, placebo-controlled, parallel-arm 1-year study of AD109 in adults with OSA who are intolerant of or refuse PAP therapy.
  • “Studying AD109 across a broad range of people who have OSA is an important consideration in the LunAIRo Study.

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Retrieved on: 
Thursday, May 9, 2024

This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy.

Key Points: 
  • This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy.
  • Within the diabetes field more broadly we are seeing the rise of innovative delivery devices, including longer-wear and miniaturised pumps that are continually improving treatment options for patients.
  • This collaboration is one of many we hope to enable, to further enhance the benefits of these next-generation devices.”
    Gary Dulak, Senior Director, New Venture Programs Medtronic Diabetes, said: “Medtronic Diabetes is a pioneer in implantable insulin pump systems for people living with type 1 diabetes, who are unable to tolerate conventional therapy that delivers insulin subcutaneously (under the skin).
  • With intraperitoneal therapy via an implantable insulin pump system, insulin delivery is targeted for direct absorption by the liver via the implantable pump.

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, May 8, 2024

CASGEVY is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals established in 2015.

Key Points: 
  • CASGEVY is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals established in 2015.
  • CRISPR Therapeutics has two next-generation approaches with the potential to significantly expand the addressable population with SCD and TDT.
  • G&A Expenses: General and administrative expenses were $18.0 million for the first quarter of 2024, compared to $22.4 million for the first quarter of 2023.
  • Collaboration Expense: Collaboration expense, net, was $47.0 million for the first quarter of 2024, compared to $42.2 million for the first quarter of 2023.

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
Wednesday, May 8, 2024

Enrollment in this study continues, and Sana expects to share more data in 2024.

Key Points: 
  • Enrollment in this study continues, and Sana expects to share more data in 2024.
  • The trial has begun enrollment, and Sana expects to share initial data in 2024.
  • The trial has begun enrollment, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects to share initial data in the first half of 2024.